Back to Screener

Chemed Corporation (CHE)

Price$422.84
Value ScoreD
Growth ScoreD
Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-16.61%
Price vs S&P 500 (4W)-3.97%
VGM Score37.10
Market Capitalization$5.66B
P/E Ratio (Annual)21.34x
Indicated Dividend Yield (Annual)0.56%

All Metrics

P/CF (Annual)14.58x
Book Value / Share (Quarterly)$64.15
P/TBV (Annual)6.76x
Indicated Dividend (Annual)$2.40
Revenue Growth (3Y)5.82%
Cash Flow / Share (Quarterly)$28.53
Payout Ratio (TTM)12.53%
Price vs S&P 500 (YTD)-11.27%
Gross Margin (TTM)32.38%
Net Profit Margin (TTM)10.23%
EPS (TTM)$18.36
10-Day Avg Trading Volume0.20M
EPS Excl Extra (TTM)$18.36
Revenue Growth (5Y)4.00%
EPS (Annual)$18.34
Dividend / Share (Annual)$2.24
ROI (Annual)26.78%
Gross Margin (Annual)32.54%
Net Profit Margin (5Y Avg)11.84%
Cash / Share (Quarterly)$1.28
P/E Basic Excl Extra (TTM)21.79x
Revenue Growth QoQ (YoY)1.63%
EPS Growth (5Y)-1.20%
P/E Normalized (Annual)21.34x
ROA (Last FY)17.24%
Revenue Growth TTM (YoY)2.07%
EBITD / Share (TTM)$27.74
ROE (5Y Avg)30.60%
Operating Margin (TTM)12.91%
Cash Flow / Share (Annual)$23.74
P/B Ratio6.67x
P/B Ratio (Quarterly)6.51x
Net Income / Employee (Annual)$16,800
EV / Revenue (TTM)2.26x
Net Interest Coverage (TTM)79.50x
ROA (TTM)16.20%
EPS Growth QoQ (YoY)-0.35%
EV / EBITDA (TTM)14.59x
EPS Incl Extra (Annual)$18.34
Current Ratio (Annual)1.05x
Quick Ratio (Quarterly)0.72x
3-Month Avg Trading Volume0.25M
52-Week Price Return-25.61%
EV / Free Cash Flow (Annual)17.65x
P/E Incl Extra (TTM)21.79x
Revenue / Employee (TTM)$160,700
Tangible BV / Share (Quarterly)$58.06
P/S Ratio (Annual)2.24x
Asset Turnover (Annual)1.64x
52-Week High$578.57
Operating Margin (5Y Avg)15.12%
EPS Excl Extra (Annual)$18.34
CapEx CAGR (5Y)1.32%
Tangible BV CAGR (5Y)2.74%
26-Week Price Return-0.68%
Quick Ratio (Annual)0.90x
13-Week Price Return7.51%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)0.85x
Enterprise Value$5.75B
Revenue / Share Growth (5Y)6.65%
Asset Turnover (TTM)1.58x
Book Value / Share Growth (5Y)4.74%
Revenue / Employee (Annual)$160,000
Inventory Turnover (Annual)216.93x
Pretax Margin (Annual)14.06%
Cash / Share (Annual)$5.43
3-Month Return Std Dev41.66%
Gross Margin (5Y Avg)34.96%
Net Income / Employee (TTM)$16,400
EBITDA CAGR (5Y)-2.02%
EBITDA Interim CAGR (5Y)1.41%
ROE (Last FY)27.08%
Net Interest Coverage (Annual)70.61x
EPS Basic Excl Extra (Annual)$18.34
P/FCF (TTM)15.01x
Receivables Turnover (TTM)10.13x
EV / Free Cash Flow (TTM)15.23x
Total Debt / Equity (Quarterly)0.12x
EPS Incl Extra (TTM)$18.36
Receivables Turnover (Annual)14.30x
ROI (TTM)24.65%
Dividend Growth Rate (5Y)11.06%
P/S Ratio (TTM)2.23x
Pretax Margin (5Y Avg)15.55%
Revenue / Share (Annual)$174.96
Tangible BV / Share (Annual)$65.40
Forward P/E16.86x
Free OCF CAGR (5Y)-5.44%
Price vs S&P 500 (52W)-53.81%
P/E Ratio (TTM)21.79x
EPS Growth TTM (YoY)-10.58%
Year-to-Date Return-0.34%
5-Day Price Return-2.95%
EPS Normalized (Annual)$18.34
ROA (5Y Avg)17.80%
Net Profit Margin (Annual)10.48%
Month-to-Date Return0.34%
Cash Flow / Share (TTM)$20.11
EBITD / Share (Annual)$27.88
EPS Growth (3Y)3.53%
Operating Margin (Annual)13.37%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)12.76x
ROI (5Y Avg)27.72%
P/E Excl Extra (TTM)21.79x
LT Debt / Equity (Quarterly)0.11x
EPS Basic Excl Extra (TTM)$18.36
P/TBV (Quarterly)7.19x
Payout Ratio (Annual)11.95%
P/B Ratio (Annual)6.19x
Dividend / Share (TTM)$2.34
Inventory Turnover (TTM)229.10x
Pretax Margin (TTM)13.73%
Book Value / Share (Annual)$71.43
Price vs S&P 500 (13W)-2.24%
Net Margin Growth (5Y)-7.36%
Dividend Yield (TTM)0.57%
Beta0.54x
P/FCF (Annual)17.39x
Revenue / Share (TTM)$185.58
ROE (TTM)25.33%
52-Week Low$365.21
vGradeD
gGradeD
mGradeC
vgmGradeD
Show chart for

Earnings Surprise History

Q1 265.65est. 5.36

Analyst Recommendations

Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
3.75
3.75
3.75

About

Chemed Corp operates two primary businesses through its subsidiaries: VITAS, a leading provider of hospice and palliative care services, and Roto-Rooter, a provider of plumbing and drain cleaning services. VITAS generates the majority of the company's revenue and serves patients with terminal illnesses through a network of healthcare professionals. The company is positioned as a diversified holding company focused on maximizing shareholder value.